Navigation Links
Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
Date:11/23/2009

NOVATO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTP) today announced the presentation of clinical trial data on NGX426, the Company's orally administered, non-opioid, AMPA/kainate receptor antagonist, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, held on November 20-21 in San Francisco. The results of the study led by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego, suggested that NGX426 could be effective in a variety of neuropathic pain states, which are caused by damage to or dysfunction of the peripheral or central nervous system rather than stimulation of pain receptors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO )

The objective of the single center, double-blind, randomized study conducted by Dr. Wallace was to demonstrate that the orally administered prodrug NGX426, maintains the analgesic effect previously shown for the active moiety, tezampanel. Using a cross-over design, a total of 18 study subjects received single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three treatment periods. Pain was induced by injecting 250 ug (microgram) of capsaicin under the skin of the forearm at 30 minutes and 120 minutes after dosing.

The 150 mg dose showed statistically significant reductions in spontaneous pain versus placebo after the 30 minute and 120 minute capsaicin injection time points. At the 150 mg dose, reductions in elicited pain were also statistically significant versus placebo. The 90 mg dose of NGX426 showed statistical significance versus placebo after the 30 minut
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... LAUSANNE , Switzerland , ... part of Debiopharm Group ™ , is proud to ... ™ instrument. Debiopharm Diagnostics is a long-time ... portfolio. Idylla ™ Biocartis, fully ... designed to offer physicians fast and easy access ...
(Date:9/16/2014)... -- This report analyzes the worldwide markets for Animal Medication ... Anti-Infectives, Medicinal Feed Additives, and Others. The report also analyzes ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
(Date:9/16/2014)...  Chairman and CEO Bernard J. Tyson ... assume the role of interim chief information officer (CIO) ... immediately. "Kaiser Permanente is a recognized ... the high-quality care and service we provide to our ... has extensive experience in information technology. I am confident ...
Breaking Medicine Technology:Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2Global Animal Medication Industry 2Global Animal Medication Industry 3Global Animal Medication Industry 4Global Animal Medication Industry 5Global Animal Medication Industry 6Global Animal Medication Industry 7Global Animal Medication Industry 8Global Animal Medication Industry 9Global Animal Medication Industry 10Global Animal Medication Industry 11Global Animal Medication Industry 12Global Animal Medication Industry 13Global Animal Medication Industry 14Global Animal Medication Industry 15Global Animal Medication Industry 16Global Animal Medication Industry 17Global Animal Medication Industry 18Global Animal Medication Industry 19Global Animal Medication Industry 20Global Animal Medication Industry 21Global Animal Medication Industry 22Global Animal Medication Industry 23Global Animal Medication Industry 24Global Animal Medication Industry 25Global Animal Medication Industry 26Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2
... Pharmaceuticals, Inc. (Nasdaq: AMPE ), a biopharmaceutical ... (Zertane™ completed two phase III studies, Ampion™-completed ... these drugs and engaged in further drug development, today ... the US Patent Office of an additional patent that ...
... March 19, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... an emerging leader in the development, assembly, marketing ... products, today announced its financial results for the ... (Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO ) ...
Cached Medicine Technology:Ampio Strengthens Patent Protection for Lead Drug Ampion™ 2Ampio Strengthens Patent Protection for Lead Drug Ampion™ 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 2Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 3Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 4Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 5Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 6Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 7Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 8Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 9Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 10Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 11Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 12Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 13Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 14Dehaier Medical Announces 2011 Fourth Quarter and Year End Financial Results 15
(Date:9/17/2014)... progressive decline in signal transduction and insulin release, according ... in Sweden. The finding, which is published in the ... underlying age-related impairment of insulin-producing cells and diabetes. , ... many diseases, and type 2 diabetes is no exception. ... of developing type 2 diabetes if their insulin-producing cells ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 The ... serving Westchester, Putnam and Dutchess Counties in New ... clinical affiliation agreement with the Mount Sinai Health ... providing integrated and coordinated care for the communities ... both Mount Sinai and MKMG will work together ...
(Date:9/17/2014)... September 17, 2014 “North America ... market data on the North America Gynecological Devices ... US dollars, volume (in units) and average prices ... Female Sterilization Devices (Transcervical Sterilization ... and Rings)) , Endometrial Ablation Devices ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Lintelus, ... announced today it has released Lintelus Meeting Version ... meetings and corporate events. The newest release includes ... and document management capabilities and allow a more ... , Lintelus Meeting 3.1 offers product advancements ...
(Date:9/17/2014)... Chesterbrook, PA (PRWEB) September 17, 2014 ... costs and increase efficiency. Today, Pharmacy Healthcare Solutions, ... Reporting, a web-based analysis and forecasting tool that ... while maximizing the impact of medications on improved ... TARxGET Reporting uses pharmacy purchase data to identify ...
Breaking Medicine News(10 mins):Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Mount Sinai Health System Partners with Mount Kisco Medical Group to Enhance Health Care Options for Residents of Lower Hudson Valley 2Health News:Mount Sinai Health System Partners with Mount Kisco Medical Group to Enhance Health Care Options for Residents of Lower Hudson Valley 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 2Health News:Pharmacy Healthcare Solutions Launches TARxGET™ Reporting 3
... ... ... Plastic Surgeons (ASPS) is bringing its popular Hot Topics in Plastic Surgery panel directly to ... can get answers to questions on emerging procedures, trends, and new technologies while engaging in ...
... Oct. 26 With the fall and winter influenza ... Prevention anticipates an even greater impact than the spring ... and businesses affected. SunGard Availability Services today outlined the ... addressed in developing pandemic plans to improve ...
... SOUTH PASADENA, Calif., Oct. 26 An evening under ... hundreds of distinguished guests from the State, local cities ... Cancer Center officially opened with a ceremonial ribbon cutting ... Antonovich and California Assemblymember Ted Lieu paid special recognition ...
... in 30 children and young adults shows good early ... with certain heart defects have impaired blood flow from ... the lungs, requiring implanted devices (known as right-ventricular outflow ... fail over time, and children typically face multiple open-heart ...
... , FARMINGTON HILLS, Mich., Oct. 26 ... flu will cause them to avoid shopping on traditionally busy retail ... Omnibus Study. , This concern stems from a consumer fear of ... the last 12 months. Some of the Morpace respondents indicated that ...
... Research Inc. (TSX:NRI), today responded to a request from ... behalf of the Toronto Stock Exchange following recent trading ... policy not to comment on market rumours or speculation, ... as previously disclosed, it anticipates receiving a decision from ...
Cached Medicine News:Health News:Plastic Surgeons to Discuss Cleavage Rejuvenation, Do-It-Yourself Lasers and Other Hot Topics with the Media 2Health News:SunGard Availability Services Addresses the Business, Operational and Workforce Issues Involved in Pandemic Planning 2Health News:SunGard Availability Services Addresses the Business, Operational and Workforce Issues Involved in Pandemic Planning 3Health News:SunGard Availability Services Addresses the Business, Operational and Workforce Issues Involved in Pandemic Planning 4Health News:South Pasadena Cancer Center Grand Opening Brings State and City Officials Together for an Evening 2Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 2Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 3Health News:Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries 4Health News:Morpace Reports: H1N1 Flu Could Adversely Impact Holiday Shopping Season 2Health News:Nuvo Research responds to increased trading activity 2
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
... MMA/VP material and has a high water content ... the base curve and total diameter as specified ... a power range of -30.00DS to +30.00DS,Simplon Bandage ... therapeutic applications including the controlled on-eye delivery of ...
Foreign body spud very thin, lightly curved and rounded tip....
... Manufactured from premium ... with high oxygen permeability. ... design. Recommended for the ... erosions and abrasions. bullous ...
Medicine Products: